ITCC-P4 is a European project created to accelerate pediatric cancer research, under the IMI-2 work programme.

In pediatric medicine there is a great need to compress the development times of specific drugs for pediatric cancers. The availability of adequate and representative experimental models of human tumors, as well as preclinical drug efficacy studies are essential to meet the clinical need for therapies dedicated to pediatric patients.

The primary objective of the project is the creation of a platform of approximately 400 experimental models representative of all pediatric cancers, including rare variants, to be used to bridge the interaction gap between academic basic research and new drug development.

The Laboratory of Experimental Oncology participates in the project as part of the national oncological network of the Ministry of Health "Alliance Against Cancer".

Project: ITCC-p4 - “ITCC PEDIATRIC PRECLINICAL POC PLATFORM”
Acronym: ITCC-p4
Initiative: INNOVATIVE MEDICINES INITIATIVE 2 JOINT UNDERTAKING (IMI2 JU)
Call: IMI2-2015-07-05
Grant Agreement: 116064
Funding body: IMI FUNDING
Duration: 01/01/2017-31/12/2023
Principal Invastigator: Katia Scotlandi
Total funded IOR: 128.775,00€